CD276 and non-small cell lung carcinoma: Among the ligands belonging to the B7 family, including PD-L1, PD-L2, B7-H3, and B7-H4, PD-L1 is the major membrane inhibitory ligand and the most studied in non-small cell lung cancer (NSCLC) clinical trials.34